thalidomide-o-c-6-nh2

Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.

Thalidomide-NH-C2-PEG3-OH (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-) is an E3 ligase ligand-linker conjugate.

Thalidomide-NH-PEG1-NH2 hydrochloride (4-[(2-(2-Aminoethoxy)ethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl) is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and a linker[1].

Thalidomide-O-CH2CONH-CH2COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) is a synthesized compound that functions as an E3 ligase ligand-linker conjugate.

Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Boc-NH-O-C1-NHS ester, an alkyl ether-based PROTAC linker, is utilized in PROTAC synthesis.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Pomalidomide-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-NH-CH2-COOH ((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine) is a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-COOH (Cereblon ligand 3) is a Thalidomide-based Cereblon ligand utilized for recruiting the CRBN protein and can be linked to a protein ligand via a linker to create PROTACs.

Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6) is a synthesized compound combining a Thalidomide-based cereblon ligand with a linker, serving as an E3 ligase ligand-linker conjugate for the synthesis of PROTACs[1].

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11) is a Thalidomide-based synthetic E3 ligase ligand-linker conjugate, consisting of a cereblon ligand and a linker, used in the production of PROTACs (proteolysis-targeting chimeras).

Thalidomide-NH-C10-NH2 hydrochloride, a thalidomide-derived cereblon ligand, facilitates CRBN protein recruitment and, when conjugated with a linker, forms PROTACs [1].

Thalidomide-5-NH-PEG1-NH2 hydrochloride is a Thalidomide-based cereblon ligand designed for CRBN protein recruitment. It facilitates the formation of PROTAC molecules by linking to target protein ligands, such as THAL-SNS-032, via a connector.

Thalidomide-NH-PEG4-Ms is a conjugate that consists of a cereblon ligand based on Thalidomide and a linker molecule, which serves as a ligand-linker moiety for E3 ligase. This conjugate is specifically designed as a degrader for PROTAC BCL-XL, known as XZ739.

Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].

Thalidomide-O-C7-NH2 is a synthesized conjugate compound comprising an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand based on Thalidomide and a linker that is commonly employed in PROTAC technology.

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound serving as an E3 ligase ligand-linker, featuring a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for use in PROTAC technology.

BnOH-NH-bis-(C2-S)-propane-O-isoprene ester (PROTAC Linker 29) is an alkyl ether-based linker used mainly for synthesizing PROTACs.

Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].

Thalidomide-NH-PEG7 is a synthesized conjugate of an E3 ligase ligand and linker, intended for use in antibody-drug conjugates (ADCs). It can be attached to a protein ligand via a linker to form PROTAC iRucaparib-AP6, a highly selective degrader of PARP1[1].

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].

Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate, combining the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly used in PROTAC technology. [1]

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized E3 ligase ligand-linker conjugate, incorporating the cereblon ligand from Pomalidomide and a linker used in PROTAC technology. It facilitates targeted protein degradation by modulating E3 ligase activity, thereby enabling the selective elimination of specific proteins of interest.

Thalidomide-NH-(CH2)2-NH2 TFA, an alkyl-modified derivative of Thalidomide, functions as a Cereblon ligand to recruit CRBN proteins and serves as a crucial intermediate in the synthesis of CRBN-based PROTAC molecules targeting the SHP2 protein.

2-(2-(6-Chlorohexyloxy)ethoxy)ethanamine hydrochloride [catalog number: T64585] is a valuable organic compound for life sciences research.

Thalidomide-5-O-C10-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and, when linked to a protein ligand, forms PROTACs [1].

Thalidomide-5-O-C12-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and, when linked to a ligand for protein, forms PROTACs [1].

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC5 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Pomalidomide - linker 4 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is an E3 ligase ligand-linker conjugate designed for targeting the EED protein in PROTAC applications[1].

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate composed of an E3 ligase ligand-linker that integrates a Thalidomide-based cereblon ligand and a linker moiety. This compound is used as a component in PROTAC BRD2 BRD4 degrader-1, a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

Thalidomide-O-C8-NH2 is a chemically synthesized conjugate that combines a cereblon ligand derived from Thalidomide with a linker utilized in PROTAC technology. It functions as an E3 ligase ligand-linker conjugate.

Thalidomide-O-amide-C5-NH2 is a chemically synthesized E3 ligase ligand-linker conjugate, combining a cereblon ligand derived from Thalidomide with a linker commonly employed in PROTAC technology.

Thalidomide-NH-C8-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate composed of a cereblon ligand derived from Thalidomide and a linker commonly used in PROTAC technology.

Thalidomide-NH-C8-NH2 is a synthetic conjugate comprising an E3 ligase ligand-linker, which merges a cereblon ligand derived from Thalidomide with a specific linker used in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates a cereblon ligand derived from Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].

β-Estradiol-6-one 6-(O-carboxymethyloxime) is an alkyl chain-based PROTAC linker used for PROTAC synthesis [1].

Thalidomide-O-C7-acid is a compound synthesized as an E3 ligase ligand-linker conjugate, consisting of a cereblon ligand derived from Thalidomide and a linker commonly used in PROTAC technology.

Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate combining a Thalidomide-based cereblon ligand with a (PROTAC) technology linker, acting as an E3 ligase ligand-linker conjugate to enable targeted protein degradation.